Inmedix® announces the US launch of its FDA-cleared CloudHRV™ System at the 2025 Rheumatology Winter Clinical Symposium.

February 23, 2025 07:34 PM AEDT | By EIN Presswire
 Inmedix® announces the US launch of its FDA-cleared CloudHRV™ System at the 2025 Rheumatology Winter Clinical Symposium.
Image source: EIN Presswire

Precision heart rate variability (HRV) launched first to rheumatologists.

NORMANDY PARK, WA, UNITED STATES, February 23, 2025 /EINPresswire.com/ -- Inmedix®, Inc. (“Inmedix”) announced the US commercial launch of its CloudHRV™ System diagnostic to rheumatologists at the Rheumatology Winter Clinical Symposium (RWCS) in Wailea, Maui, February 12-15, 2025. On January 17, 2025, the US FDA cleared the Inmedix CloudHRV System for US commercialization. Its intended use is as a heart rate variability (HRV) diagnostic to be applied in the clinical setting at the clinician’s discretion.

This is the first system cleared by the FDA as a cloud-based, heart rate variability (HRV) diagnostic calculated from a high-fidelity 5-min electrocardiogram (ECG) which also includes Bayefsky indices of parasympathetic and sympathetic activity of the autonomic nervous system (ANS). It represents a milestone in modern HRV assessment with scalability, precision and affordability.

The autonomic nervous system (ANS) is a fundamental component of the brain which both monitors and directs a broad range of human physiologies, from cardiovascular, gastrointestinal, neurology, endocrine, psychiatry, pain, sleep and the immune system (1).

For medical grade HRV, a precision ECG is required to identify each heartbeat and to measure the precise timing between beats. These ECG measurements of heart rate (pulse) variability over time reflect how the ANS influences cardiac rhythm during breathing. Subsequently, mathematical formulae can be applied to render HRV indices of sympathetic and parasympathetic activity (2).

“Achieving FDA clearance of the Inmedix CloudHRV System was a major milestone,” said Inmedix CEO and Co-founder Andrew J Holman MD, “and we were honored to launch it commercially at one of the premier US rheumatology meetings. The annual RWCS, now in its 18th year, continues to be an educational leader in diligent, peer-reviewed and patient-centered rheumatology science and clinical care.”

References
1. Otto Appenzeller, Guillaume J. Lamotte, Elizabeth A. Coon. Introduction to Basic Aspects of the Autonomic Nervous System (Sixth Edition). Academic Press, 2022,
2. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996 Mar;17(3): 354-81.

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress modulated within the brain by the autonomic nervous system (ANS).

NOTICE:

This Press Release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies, effectiveness of its research, product capabilities and the market’s demand for its respective products. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing, regulatory approval, developments in raw material, personnel costs, sales as well as legislative, fiscal, and other regulatory measures. Any forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.

Andrew Holman
Inmedix Inc.
+1 206-412-5347
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.